

REGENERATIVE MEDICINE MARKETS *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers



TABLE OF CONTENTS

1.	Overview	17
1.1	Statement of Report	17
1.2	Scope of this Report	19
1.3	Methodology	19
1.4	Executive Summary	20
2.	Regenerative Medicine: An Overview of Segments	22
2.1	Tissue Engineering	22
2.1.1	Tissue-Engineered Skin	23
2.1.2	Tissue-Engineered Cartilage	23
2.1.3	Tissue-Engineered Bone	23
2.1.4	Tissue-Engineered Peripheral Nerves	23
2.1.5	Tissue-Engineered Cornea	24
2.1.6	Tissue-Engineered Blood Vessels	24
2.2	An Overview of Tissue Engineering and Regenerative Medicine (TERM)	24
2.2.1	Tissue-Engineered Products and their Applications	25
2.2.1.1	Skin, Cartilage, Bone and Urological Applications	26
2.2.1.2	Cardiovascular Applications	26
2.2.1.3	Neurological Applications	27
2.2.1.4	Pancreas, Liver and Kidney Applications	27
2.2.1.5	Ophthalmic Applications	28
2.2.1.6	Dental Applications	28
2.2.1.7	Autologous and Allogeneic Products	28
2.2.2	Geographic Distribution of TERM Firms in the Five Focus Countries	28
2.3	Cell Therapy	31
2.3.1	Number of Patients Treated between 1988 and 2010 by Regenerative Medicine Therapies	33
2.3.2	Cell Culture Products	34
2.3.2.1	In vitro Test Kits	35
2.3.2.2	Suppliers of Cells and Tissues	36
2.3.2.3	Suppliers of Culture Media and Reagents	37
2.3.2.4	Equipments for Stem Cell Research	37
2.3.2.5	Computer Software for Stem Cell Research	38
2.3.3	Overall Picture of Cell Therapy Industry	40
2.3.3.1	The Size of Cell Therapy Industry	40
2.3.3.2	The Age, Size and Location of Firms	41
2.3.3.3	Technology and Disease Focus	43
2.3.4	Cell Therapy Products and Companies	43
2.3.4.1	First Generation (Non-Stem Cell-based) Primary Products	45
2.3.4.2	Second Generation (Stem Cell-based) Primary Products	46
2.3.4.3	Secondary Products	46
2.3.4.4	Products in Development	47
2.3.5	The Disease Focus of Clinical Trials	47
2.3.5.1	Stem Cell Industry Pipeline	48
2.3.6	Industry Collaboration in Stem Cell Space	50
2.3.6.1	Commercial Success in Stem Cell Industry	50
2.3.6.2	Major Shift to Stem Cells from Non-Stem Cell Technologies	51
2.3.6.3	Challenges to Commercial Development of Cell Therapies	51
2.3.6.4	Partnership of Stem Cell Companies with Large Pharmaceutical Companies	53
2.3.6.5	Strategic Approaches for Cell-based Companies	53
2.3.6.6	The Need for Support from Large Pharmaceuticals	55
2.4	Scaffolding Biomaterials	55
2.4.1	Biomaterial Scaffolds in Regenerative Medicine	56
2.5	Growth Factors	58

3.	Regenerative Medicine: The Next Evolution of Medical Treatments	60
3.1	Scope of this Chapter	60
3.2	Need for Regenerative Medicine	60
3.3	Current State of Regenerative Medicine	60
3.4	Future of Regenerative Medicine	61
3.5	Number of Products in Pipeline	61
3.6	Projected Timeline for Regenerative Medicine	65
3.7	Regenerative Medicine Products in the Market	66
3.7.1	Medtronic's Infuse Bone Graft and the LT-Cage Device	66
3.7.2	Genzyme's Carticel	67
3.7.3	Stryker's OP-1	68
3.7.4	Osyris/Nuvasive's Osteocel®	68
3.7.5	RTI's Spinal Implants	69
3.7.6	Organogenesis' Apligraf®	69
3.7.7	Advanced BioHealing's Dermagraft®	70
3.7.8	Integra's Bilayer Matrix Wound Dressing	70
3.7.9	LifeCell's Alloderm®	70
3.7.10	Cytori Therapeutics' Celution®	71
3.8	Other Products of Importance in Regenerative Medicine	72
3.8.1	Tissue-Engineered Wound Healing Products	72
3.8.1.1	Oasis®	73
3.8.1.2	Permacol™	73
3.8.1.3	EZ-Derm®	73
3.8.1.4	Matriderm®	73
3.8.1.5	TransCyte®	74
3.8.1.6	ICX-SKN®	74
3.8.1.7	OrCel®	75
3.8.1.8	Epicel®	75
3.8.1.9	Myskin™	75
3.8.1.10	VCT01™	76
3.8.2	ICX-TRC—Hair Regeneration Therapy	76
3.8.3	Cartilage Regeneration	76
3.8.3.1	Novocart™	76
3.8.3.2	BioSeed®-C	76
3.8.3.3	BioSeed®-Oral Bone	77
3.8.3.4	Chondrotissue®	77
3.8.3.5	co.don Chondrotransplant	77
3.8.3.6	co.don Chondrotransplant® DISC	77
3.8.3.7	co.don Chondrosphere®	77
3.8.3.8	co.don Osteotransplant® DENT	77
3.8.3.9	MACI® Implant	77
3.8.3.10	Cartilink-3®	77
3.8.3.11	Accell Evo3® Demineralized Bone Matrix	78
3.8.3.12	OsSatura BCPT™	78
3.8.4	Mozobil	78
4.	Market Analysis of Regenerative Medicine Sector	79
4.1	Scope of this Chapter	79
4.1.1	Market for Regenerative Medicine Products	79
4.1.2	The Different Characteristics of Regenerative Medicine Industry in the Recent Past	82
4.1.3	Potential Market for Regenerative Medicine in the U.S.	83
4.2	Global Market for Stem Cells	84
4.3	Market for Cell Therapy in the U.S.	85
4.4	Global Market for Cord Blood Stem Cells	85
4.4.1	Public Cord Blood Banks	86
4.4.2	Private Cord Blood Banks	86

5.	Business Models and Requirements for a Successful Regenerative Medicine Industry	88
5.1	Scope of this Chapter	88
5.1.1	The Limited Success Achieved by the Regenerative Medicine Products	88
5.1.2	Business Models in Regenerative Medicine	88
5.1.3	Current Model for Autologous Cell Therapies	90
5.1.4	Current Models for Allogeneic Cell Therapies	91
5.1.5	Key Factors for Successful Business Models for Cell Therapies	92
5.2	Commercial Manufacturing of Cell Therapy Products: Requirements	93
5.2.1	Elements of Commercial Manufacturing	93
5.2.1.1	Regulatory Requirements	93
5.2.1.2	Manufacturing Process Scale	93
5.2.1.3	In-House Manufacturing	94
5.2.1.4	Contract Manufacturing: Commercial and Academic	94
6.	Diseases with Potential Applications for Regenerative Medicine	97
6.1	Regenerative Medicine and Diabetes	99
6.2	Regenerative Medicine for Cardiac Repair	100
6.3	Regenerative Medicine in Orthopedics	100
6.3.1	Orthobiologics in Orthopedics	100
6.3.2	Growth Factor Therapies in Orthopedics	101
6.3.3	Stem Cell Therapies in Orthopedics	101
6.4	Regenerative Medicine in Liver Diseases	101
6.4.1	Hepatocyte-like Cells for Liver Disease	102
6.4.2	Cell Therapy for Liver Cirrhosis	102
6.4.3	CD 34+ Cells	102
6.5	Regenerative Medicine in Retinal Replacement Therapy	102
6.5.1	Retinal Transplantation	102
6.6	Regenerative Medicine in Central Nervous System (CNS) Disorders	103
6.6.1	Clinical Activity for Stem Cell Transplantation into the CNS	103
7.	Current Stem Cell Research and Federal Funding in the U.S.	104
7.1	Scope of this Chapter	104
7.2	Stem Cell Policies in North America	104
7.3	Stem Cell Policies in South America	105
7.4	Stem Cell Policies in Europe	105
7.5	Stem Cell Policies in Asia/Oceania	107
7.6	Stem Cell Policies in Africa	108
7.7	Stem Cell Research and California Institute for Regenerative Medicine (CIRM)	108
7.7.1	CIRM Collaborative Funding	109
7.7.2	CIRM's funding for Clinical Applications	110
7.7.3	Early Translational Awards	110
7.7.4	CIRM's Disease Team Awards	111
7.8	Stem Cell Research Programs in Connecticut Department of Public Health	111
7.8.1	Seed Grant Awards from Connecticut Stem Cell Research Program in 2010	111
7.8.2	Established Investigator Awards from Connecticut Stem Cell Research Program in 2010	111
7.8.3	Group Project Awards from Connecticut Stem Cell Research Program in 2010	112
7.8.4	Core Facility Awards from Connecticut Stem Cell Research Program in 2010	113
7.8.5	Maryland Technology Development Corporation (TEDCO)	113
7.8.6	TEDCO's Fort Detrick Technology Transfer Initiative (FDTTI)	113
7.8.7	J&J Investment Fund	113
7.8.8	TEDCO's NAVAIR Technology Insertion (NAVTI) Program	113
7.8.9	TEDCO's TechStart Program	113
7.8.10	TEDCO's University Technology Development Fund (UTDF)	113
7.8.11	TEDCO's Working Capital Loan Fund	113
7.8.12	Maryland Technology Transfer and Commercialization Fund (MTTCF)	113

7.8.13	Maryland Stem Cell Research Fund	114
7.9	The New Jersey Commission on Science and Technology (NJCSST)	114
7.9.1	Investigator Initiated Research Projects and Innovative (IIRP), Developmental or Exploratory Activities (IDEA) in Stem Cell Research	115
7.9.2	Targeted RFA for Investigation of iPS and Other Derivation Approaches	116
7.9.3	Shared Facilities/Resources and Equipment/Instrumentation for Stem Cell Research	116
7.9.4	Consortia Planning Awards	116
7.9.5	Institutional Development	116
7.10	Center for Stem Cell and Regenerative Medicine	116
7.11	Global Funding for Regenerative Medicine	117
7.12	Federal Funding of Stem Cell Research in the U.S.: Past and Present	117
7.12.1	The U.S. National Institute of Health (NIH) Guidelines to hESC Research	118
7.12.2	Types of Research Ineligible for NIH Funding	118
7.12.3	NIH's Leadership in Providing Funds for Stem Cell Research	118
7.12.4	NIH Guidelines Addressing the Projected Growth of Stem Cell-related Clinical Trials	118
7.12.5	Federal Agencies Providing Funds for Stem Cell Research	118
8.	Company Profiles	120
8.1	Aastrom Biosciences, Inc.	120
8.1.1	Aastrom's Clinical Trial Programs	120
8.1.1.1	Dilated Cardiomyopathy	120
8.1.1.2	Critical Limb Ischemia	120
8.1.1.3	Osteonecrosis of the Femoral Head	120
8.1.1.4	Other Bone Disorders	120
8.1.2	Product Development	121
8.1.3	Aastrom's Cell Manufacturing	121
8.1.4	Aastrom's Business Performance	121
8.2	Advanced Cell Technology, Inc. (ACT)	122
8.2.1	ACT's Cellular Reprogramming	122
8.2.2	ACT's Stem Cell Differentiation	123
8.2.2.1	ACT's Retinal Pigment Epithelium Program	123
8.2.2.2	ACT's Hemangioblast Program	123
8.2.2.3	ACT's Adult Stem Cell Program	123
8.2.3	ACT's Intellectual Property	123
8.2.4	ACT's Business Performance	124
8.2.5	ACT's Investment in Research and Development	125
8.3	Aldagen, Inc.	125
8.3.1	Aldagen's ALD-201	126
8.3.2	Aldagen's ALD-301	126
8.4	Altrika Ltd.	126
8.4.1	Myskin™	126
8.4.2	Cryoskin™	127
8.4.3	Altrika's Future Products	127
8.4.3.1	Lyphoderm	127
8.4.3.2	Corneal Bandage	127
8.4.3.3	Leukodepletion Filters	128
8.5	Alseres Pharmaceuticals, Inc.	128
8.5.1	Alseres' Product Pipeline	128
8.5.1.1	Celthrin®—a Rho Inhibitor	129
8.5.1.2	Inosine	129
8.5.1.3	Oncomodulin and ALSE-100	130
8.5.1.4	Altropane®—PD	130
8.5.2	Alseres' Science and Technology	131
8.5.2.1	Nerve Repair Pathways	131
8.5.2.2	The Pro-Regenerative Pathway	132
8.5.2.3	The Anti-Regenerative Pathway	132

8.5.2.4	Molecular Imaging	132
8.5.2.5	Dopamine Transporter	133
8.6	Amgen, Inc.	134
8.6.1	Amgen's Marketed Products	135
8.6.1.1	Aranesp® (Darbepoetin Alfa)	135
8.6.1.2	Epogen® (Epoetin Alfa)	136
8.6.1.3	Neulasta® (Pegfilgrastim)/Neupogen® (Filgrastim)	136
8.6.1.4	Enbrel® (Etanercept)	137
8.6.1.5	Sensipar® (cinacalcet)	138
8.6.1.6	Vectibix® (Panitumumab)	138
8.6.1.7	Nplate® (Romiplostim)	139
8.6.2	Amgen's Marketing and Distribution	139
8.6.3	Amgen's Overall Business Performance	140
8.7	Amorcyte, Inc.	141
8.7.1	Amorcyte's Technology	141
8.7.1.1	AMR-001	141
8.8	AnGes MG, Inc.	142
8.8.1	AnGes' Genetic Medicine	142
8.8.2	HGF Genetic Medicine	142
8.8.3	Hemagglutinating Virus of Japan (HVJ) Envelope Vector	143
8.8.4	NF κB Decoy Oligodeoxynucleotide	143
8.9	Angioblast Systems, Inc.	145
8.9.1	Angioblast's Technology and Applications	145
8.9.1.1	Allogenic Adult Stem Cells	145
8.9.1.2	Protein Therapeutics	145
8.9.1.3	Gene Slicing	145
8.10	Angion Biomedica, Corp.	146
8.10.1	HGF and c-Met Signaling in Tissue Repair and Organ Regeneration	147
8.10.2	PARP-1	147
8.10.3	TGF β1	148
8.11	Ars Arthro Biotechnology, Inc.	148
8.11.1	CaReS®	148
8.11.2	Fibrocell	148
8.11.3	Fibroplus	149
8.12	Arteriocyte Medical Systems, Inc.	149
8.12.1	Blood Pharming	149
8.12.2	Cardiac Ischemia	149
8.12.3	Critical Limb Ischemia	149
8.12.4	Malaria Research	150
8.12.5	Orthopedic Regenerative Medicine	150
8.12.6	Proliferative Diabetic Retinopathy	150
8.12.7	Wound Healing	150
8.13	Athersys, Inc.	151
8.13.1	Athersys' Pipeline	151
8.13.2	MultiStem for Stem Cell Therapy	151
8.13.3	MultiStem for BM Transport Support	152
8.13.4	MultiStem for Acute Myocardial Infarction	152
8.13.5	MeriStem for Stroke	152
8.13.6	Treatments for Obesity	153
8.13.7	Histamine H3 Receptor Antagonists	153
8.13.8	Athersys' Collaborations and Partnerships	153
8.13.8.1	Collaboration with Pfizer	153
8.13.8.2	Collaboration with Angiotech	153
8.13.8.3	Collaboration with Bristol-Myers Squibb	153
8.13.9	Athersys' Research and Development	153
8.13.10	Athersys' Business Performance	154

8.14	BeFutur Biotechnologies	154
8.14.1	BeFutur's Technologies	155
8.14.1.1	Cells and Tissue Engineering	155
8.14.1.2	Serum Free Technology	155
8.15	BioE, Inc.	155
8.15.1	BioE's Products	155
8.16	Bioheart, Inc.	155
8.16.1	Bioheart's Product Candidates	156
8.16.1.1	MyoCell®	156
8.16.1.2	MyoCell SDF-1	156
8.16.1.3	TGI 1200 Cell Isolation System	156
8.16.1.4	Bioheart 3370®	156
8.16.2	Bioheart's Patents and Proprietary Rights	157
8.17	BioLine Rx	157
8.17.1	BioLine's Product Pipeline	157
8.17.1.1	BL-1020 Schizophrenia	157
8.17.1.2	BL-1040 for Acute Myocardial Infarction	157
8.17.1.3	BL-5010 for Skin Lesions	158
8.17.1.4	BL-1021 for Neuropathic Pain	158
8.17.1.5	BL-2030 for Inflammation	158
8.17.1.6	BL-1023 for Parkinson's disease	158
8.17.1.7	BL-4010 for Cancer	158
8.17.1.8	BL-4040 for Acute Kidney Failure	158
8.17.1.9	BL-5030 for Thromboembolic Diseases	158
8.17.1.10	BL-5040 for Cachexia and Inflammatory Bowel Disease	159
8.18	BIOMET	159
8.18.1	BIOMET 3i	159
8.18.2	Clotalyst® Autologous Serum Collection System	159
8.18.3	BioCUE™ Platelet Concentration System	159
8.19	BioMimetic Therapeutics, Inc.	160
8.19.1	BioMimetic's Product Candidates	160
8.19.2	BioMimetic's Research and Development	161
8.20	BioSafe Group SA	161
8.20.1	Sepax	162
8.20.2	Sepax System in Adult Stem Cell Banking	162
8.20.3	Coolmix	162
8.20.4	SepaxNet	163
8.21	BioTime, Inc.	163
8.21.1	BioTime's Stem Cell Products for Regenerative Medicine	164
8.21.2	BioTime's Embryome Database	164
8.21.3	BioTime's Progenitor and hES Cell Lines	164
8.21.4	BioTime's hES Cells Carrying Genetic Diseases	164
8.21.5	BioTime's ESspan™ Cell Growth Media	164
8.21.6	BioTime's ESpy™ Cell Lines	164
8.21.7	BioTime's Licensed Stem Cell Technology and Stem Cell Product Development Agreements	165
8.21.7.1	Wisconsin Alumni Research Foundation	165
8.21.7.2	ACTCellerate™ Technology	165
8.21.7.3	The iPS Technology	165
8.21.7.4	Lifeline	165
8.21.7.5	BioTime's Stem Cell Agreement with Reproductive Genetics Institute	165
8.21.8	BioTime's Plasma Volume Expanders and Related Products	165
8.21.8.1	Hextend	165
8.21.8.2	PentaLyte	166
8.22	Biovest International, Inc.	166
8.22.1	BiovaxID Cancer Vaccine	166
8.23	BrainStorm Cell Therapeutics, Inc.	166

8.23.1	BrainStorm's Technology	166
8.23.2	BrainStorm's Stem Cell Therapy	167
8.23.3	BrainStorm Technology—NurOwn™	167
8.24	Cardio3 BioSciences	168
8.24.1	Cardio3's Product Pipeline	168
8.24.1.1	C-Cure®	169
8.24.1.2	C-Cure2	169
8.24.1.3	Allo-Cure	169
8.24.1.4	G-Cure	169
8.24.1.5	C-Cath	169
8.24.2	Cardio3's Investors	169
8.25	CardioPolymers, Inc.	170
8.25.1	CardioPolymer's Products	170
8.25.1.1	Algisyl-LVR™	170
8.25.1.2	Plexisyl-AF™	171
8.25.2	CardioPolymer's Investors	171
8.26	CaridianBCT	171
8.26.1	Trima Accel® Automated Blood Collection System	171
8.26.2	Spectra Optia® Apheresis System	172
8.26.3	COBE® Spectra Apheresis System	172
8.26.4	Elutra® Cell Separation System	172
8.26.5	Atreus® Whole Blood Processing System	173
8.26.6	OrbiSac® System	173
8.26.7	COBE® 2991 Cell Processor	173
8.27	Cardium Therapeutics, Inc.	174
8.27.1	Cardium Biologics	174
8.27.2	Cardium's Tissue Repair Company	174
8.27.3	Cardium's Gene Activated Matrix™ (GAM) Technology	175
8.27.4	Cardium's Biologics and Stem Cells for Regenerative Medicine	175
8.28	Cellartis AB	175
8.28.1	Cellartis' Products	175
8.28.1.1	The hES-CMCT™ 2D: Cardiomyocyte Monolayers	175
8.28.1.2	The hES-CMCT™ 002: Cardiomyocyte Clusters	176
8.28.1.3	The hES-HEO™ 002: Hepatocyte-like Cells	176
8.28.1.4	The hES-MP™ 002.5: Mesenchymal Progenitors	177
8.28.1.5	The hES Cell Lines	177
8.28.1.6	SCED™ 461: Human ES Cells	177
8.28.1.7	Monoclonal Antibodies	178
8.28.2	Cellartis' Licensing Activities	178
8.29	Cellerix	178
8.29.1	Ontaril®	179
8.29.2	Cx501	179
8.30	Celgene Corporation	180
8.30.1	Celgene's Business Performance	180
8.30.2	Celgene's Commercial Stage Products	181
8.30.2.1	Revlimid® (Lenalidomide)	181
8.30.2.2	Thalomid® (Thalidomide)	181
8.30.2.3	Vidaza® (Azacitidine for Injection)	182
8.30.2.4	Ritalin® Family of Drugs	182
8.30.2.5	Alkeran® (Melphalan)	182
8.30.2.6	IMiDs® Compounds	182
8.30.2.7	Oral Anti-Inflammatory Agents	182
8.30.2.8	Kinase Inhibitors	182
8.30.2.9	Cellular Therapies	183
8.31	CellSeed, Inc.	183
8.31.1	CellSeed's Epithelial Cell Sheet for Corneal Regeneration	183

8.31.2	CellSeed's Regenerated Cardiac Patch	184
8.31.3	CellSeed's Epithelial Cell Sheet for Esophageal Regeneration	184
8.31.4	CellSeed's Cell Sheet for Periodontal Tissue Regeneration	184
8.31.5	CellSeed's Regenerated Cartilage Sheet	184
8.32	Cellular Dynamics International	184
8.32.1	The iCell Cardiomyocytes	185
8.32.2	Cellular Dynamics' Technology	185
8.33	Celltrix	185
8.33.1	Credurance	186
8.34	Cerco Medical	186
8.34.1	Cerco Medical's Concept	186
8.34.2	Bio-artificial Endocrine Pancreas	187
8.35	Cook Biotech, Inc.	187
8.35.1	Cook's Technology	187
8.35.2	Biodesign™ Dural Graft	188
8.35.3	Dynamatrix™ Oral Graft	188
8.35.4	SiS Ophthalmic	188
8.35.5	Oasis® Wound Matrix	188
8.35.6	Biodesign™ Staple Line Reinforcement	188
8.35.7	Biodesign™ Hiatal Hernia Graft	189
8.35.8	ECM for Pericardial Closure	189
8.35.9	ECM for Cardiac Tissue Repair	189
8.35.10	Biodesign™ 8-Layer Tissue Graft	189
8.35.11	Biodesign™ Abdominal Lock Graft	189
8.35.12	Biodesign™ Hernia Graft	190
8.35.13	Biodesign™ Inguinal Hernia Graft	190
8.35.14	Biodesign™ Umbilical Hernia Graft	190
8.35.15	Biodesign™ Anterior Pelvic Floor Graft	191
8.35.16	Biodesign™ Fistula Plug	191
8.35.17	Biodesign™ Posterior Pelvic Floor Graft	191
8.35.18	Surgisis Biodesign® Peyronie's Repair Graft	192
8.35.19	Biodesign™ Tension-free Urethral Sling	192
8.35.20	Biodesign™ Vaginal Erosion Repair Graft	192
8.35.21	AxoGuard™ Nerve Protector	193
8.35.22	AxoGuard™ Nerve Connector	193
8.35.23	FISH™ Femoral Introducer Sheath and Hemostasis Device	193
8.36	Cord Blood America (CBAI), Inc.	193
8.37	Cryo-Cell International, Inc.	193
8.37.1	Cryo-Cell's License Agreements	193
8.37.1.1	Cryo-Cell De Mexico	193
8.37.1.2	Asia Cryo-Cell Private Limited	194
8.37.1.3	Venezuela	194
8.37.1.4	China	194
8.37.1.5	Germany	194
8.37.1.6	Nicaragua	194
8.37.1.7	Pakistan	194
8.37.2	Uses of Cord Blood Stem Cells	195
8.38	Curis, Inc.	197
8.38.1	Curis' Business Performance	198
8.38.2	Curis' Research and Development	198
8.39	Cytori Therapeutics, Inc.	199
8.39.1	Cytori's Cosmetic and Reconstructive Surgery Market	200
8.39.2	Cytori StenSource® Cell Banking Market	200
8.40	Develogen AG	201
8.40.1	Develogen's Pipeline	201
8.40.1.1	DG3173—Somatostatin Analog	201

8.40.1.2	Insulin Sensitizers	201	
8.40.1.3	Beta Cell Regeneration Factor	201	
8.41	Effector Cell Institute, Inc (ECI)	202	
8.41.1	ECI's Cell-based Drug Discovery (CDD)	202	
8.41.2	ECI's Regenerative Medicine	202	
8.41.3	ECI's Cancer Therapeutic Agent Development Project (EC1301)	202	
8.41.4	ECI's Anti-Inflammatory Drug Development Project (FROUNT)	203	
8.41.5	ECI's High Throughput Screening by Automatic TAXIScan™ System	203	
8.41.6	ECI's Products	204	
8.41.6.1	TAXIScan™ System	204	
8.41.6.2	Cytorecon™	204	
8.41.6.3	TAXIScan-FL™	204	
8.42	Epistem plc	205	
8.42.1	Epistem's Cotract Research Services in Oncology	205	
8.42.2	Epistem's Xenografting Models	205	
8.42.3	Epistem's Cancer Cell Assays	205	
8.42.4	Epistem's Angiogenesis Models	206	
8.42.5	Epistem's Colon Cancer Models (Min/+)	206	
8.42.6	Epistem's Histology, IHC, ISH and Gene Expression Profiling	206	
8.42.7	Epistem's In vitro Cytotoxicity Testing	206	
8.42.8	Epistem's Plucked Hair Immunohistochemistry	207	
8.42.9	Epistem's Emerging Protein Therapeutics	207	
8.42.10	Epistem's Biomarker Technology	207	
8.43	FivePrime Therapeutics, Inc.	208	
8.43.1	FivePrime's Technology	208	
8.43.2	FivePrime's Collaborations	209	
8.44	Forticell Bioscience, Inc.	209	
8.44.1	OrCell®	210	
8.45	Gamidia Cell Ltd.	210	
8.45.1	Gamidia's Technology	210	
8.46	GeneGrafts Ltd.	211	
8.46.1	Gene Graft's Technology	211	
8.47	GenVec, Inc.	211	
8.47.1	GenVec's Product Programs	212	
8.47.1.1	TNFerade™	212	
8.47.1.2	Hearing and Balance	212	
8.48	Genzyme Corporation	212	
8.48.1	Genzyme's Business Performance	212	
8.48.2	Genzyme's Genetic Diseases Segment	213	
8.48.3	Genzyme's Hematology Oncology Segment	214	
8.48.4	Genzyme's Cardiometabolic and Renal Segment	215	
8.48.5	Genzyme's Biosurgery Segment	215	
8.48.6	Genzyme's Genetics and Diagnostics Segment	216	
8.48.7	Genzyme's Pipeline	216	
8.49	Geron Corporation	218	
8.49.1	Geron's Major Technology Platforms	218	
8.49.1.1	Role of Telomere in Cancer and Aging	218	
8.49.1.2	Human Embryonic Stem Cells: Source for the Manufacturing of Therapeutic Cells	218	
8.49.2	Commercial Opportunities for Geron's Major Technology Platforms	218	
8.49.2.1	Oncology	218	
8.49.3	Geron's Human Embryonic Stem Cell Therapies	219	
8.49.4	Geron's Patents and Proprietary Technology	219	
8.49.5	Geron's Business Performance	220	
8.49.6	Geron's Investment in Research and Development	221	
8.50	Harvest Technologies Corporation	221	
8.50.1	Harvest Technologies' Products	221	

8.50.1.1	SmartPREP®2 APC+™	221
8.50.1.2	SmartPREP 2 BMAC™	222
8.51	HemaStem Therapeutics, Inc.	222
8.51.1	Cord Blood Program	222
8.52	HepaLife Technologies, Inc.	223
8.52.1	Liver Disease	223
8.52.1.1	HepaMate™	223
8.53	Humacyte, Inc.	224
8.53.1	Humacyte's Products	224
8.54	Hydra Biosciences, Inc.	224
8.54.1	Hydra's Program	224
8.55	Intercytex Group plc	225
8.55.1	Vavelta®—Skin Repair and Rejuvenation	225
8.55.2	SHEF-1—Stem Cell Line	226
8.55.3	CX-SKN—Skin Graft Replacement for Burns and Acute Wounds	226
8.55.4	ICX-TRC—Hair Regeneration	227
8.55.5	Cyzact®—Chronic Wound Repair	227
8.56	Integra Lifesciences Holdings Corporation	227
8.56.1	Integra's Products	228
8.56.1.1	Integra's Orthopedic Product Portfolio	228
8.56.1.2	Dermal Regeneration and Engineered Wound Dressings	228
8.56.1.3	Nerve and Tendon	228
8.56.1.4	Bone Graft Substitutes for Extremity Reconstruction	228
8.56.1.5	Integra's OrthoBiologics	229
8.56.1.6	Duraplasty Products	229
8.56.2	Integra's Investment in Research and Development	229
8.56.3	Integra's Business Performance	230
8.57	International Stem Cell Corporation (ISCO)	230
8.57.1	Lifeline Cell Technology	230
8.57.2	Universal Stem Cell Bank	231
8.57.3	ISCO's Technology	231
8.58	Japan Tissue Engineering, Co., Ltd.	231
8.58.1	Autologous Cultured Epidermis	232
8.58.2	Autologous Cultured Cartilage	232
8.58.3	Autologous Cultured Corneal Epithelium	233
8.59	Karocell Tissue Engineering AB	234
8.59.1	Karocell's Autologous Cells	234
8.59.1.1	Keratinocytes	234
8.59.1.2	Melanocytes	234
8.59.1.3	Fibroblasts	234
8.59.1.4	Chondrocytes	234
8.59.1.5	Urothelial Cells	234
8.59.1.6	Karoskin™	235
8.59.1.7	Karoderm™	235
8.59.1.8	Cell Bank	235
8.59.2	Karocell's Research and Development	235
8.60	Kensey Nash Corporation	235
8.60.1	Biomaterials from Kensey	236
8.60.2	Kensey's Collagen Technology	236
8.60.3	Porous Tissue Matrix Technology	237
8.60.4	Kensey's Products	237
8.60.4.1	The Angio-Seal™ Vascular Closure Device	237
8.60.4.2	Vitoss® Scaffold Foam™	238
8.60.4.3	OsseoFit™ Porous Tissue Matrix™	238
8.60.4.4	Epi-Guide® Bioresorbable Barrier Matrix	238
8.61	Kiadis Pharma, BV	238

8.62	LifeCell	239
8.62.1	AlloDerm® Regenerative Tissue Matrix	239
8.62.2	Strattice™ Reconstructive Tissue Matrix	239
8.62.3	Cymetra® Micronized AlloDerm® Tissue	239
8.63	MaxCyte, Inc.	239
8.63.1	Advantages of MaxCyte Platform System	240
8.63.2	MaxCyte's Collaborations	240
8.63.3	MaxCyte's Application in Immunotherapy	240
8.63.4	MaxCyte's Application in Regenerative Medicine	241
8.63.5	MaxCyte's Viral Vectors and Vaccines	241
8.63.6	MaxCyte® XTS™ Scalable Transfection System	241
8.64	Mesoblast Ltd.	241
8.64.1	Mesoblast's Intervertebral Spinal Fusion	242
8.64.2	Lumbar Fusion	242
8.64.3	Cervical Fusion	242
8.64.4	Mesoblast's Intervertebral Disc Repair and Regeneration	242
8.64.5	Mesoblast's Product for Knee Osteoarthritis	242
8.64.6	Mesoblast's Investment in Angioblast Systems, Inc.	242
8.64.7	Angioblast's Product Candidate for Congestive Heart Failure	243
8.64.8	Angioblast's Product Candidate for Bone Marrow Transplantation	243
8.65	NanoCor Therapeutics, Inc.	243
8.65.1	NanoCor's Products	243
8.66	NeuralStem, Inc.	243
8.66.1	NeuralStem's Technology	244
8.66.2	NeuralStem's Research and Programs	244
8.66.3	NeuralStem's Intellectual Property	245
8.67	NeuroNova AB	246
8.67.1	NeroNova's Neurogenesis Qualifier—Technology	246
8.67.2	The sNN0029	246
8.67.3	The sNN0031	247
8.67.4	NeuroNova's Investors	247
8.68	Olympus Terumo Biomaterials Corporation	247
8.68.1	OSferion 60	248
8.68.2	Terudermis	248
8.68.3	Teruplug	248
8.68.4	Osferion	249
8.68.5	Boneceram P	249
8.69	Opexa Therapeutics, Inc.	249
8.69.1	Opexa's T-Cell Platform	249
8.69.2	Opexa's Stem Cell Platform	250
8.70	Organogenesis, Inc.	250
8.70.1	Products from Organogenesis	250
8.70.1.1	Apligraf®	250
8.70.1.2	VCT01™	250
8.70.1.3	CelTx™ for Oral Soft Tissue Regeneration	251
8.70.1.4	FortaGen®	251
8.70.1.5	FortaPerm®	251
8.70.1.6	BioSTAR®	251
8.71	Orthovita, Inc.	251
8.71.1	Orthovita's Products	252
8.71.1.1	Vitoss	252
8.71.1.2	Vitoss and Bone Defect Grafting	252
8.71.1.3	Vitoss in Spinal Fusion and Grafting	253
8.71.1.4	Vitoss and Trauma	253
8.71.1.5	Vitomatrix™ and Dental, Periodontal, Oral and Craniomaxillofacial Defects	253
8.71.1.6	Cortoss Bone Augmentation Material	253

8.71.1.7	Cortoss and Vertebral Augmentation of VCFs	253
8.71.1.8	Cortoss and Screw Augmentation	253
8.71.1.9	Orthovita's Aliquot Delivery System	254
8.71.2	Orthovita's Biosurgery Products	254
8.71.3	Partnership with Kensey for Vitoss Foam	254
8.71.4	Partnership with Angiotech for Vitagel and CellPaker	254
8.71.5	Partnership with Medafor for Vitasure	255
8.71.6	Orthovita's Business Performance	255
8.72	Osiris Therapeutics, Inc.	255
8.72.1	Osiris' Partnerships	256
8.72.2	Osiris' Technologies	256
8.72.3	Prochymal®	256
8.72.4	Chondrogen®	257
8.73	Osteotech, Inc.	257
8.73.1	Osteotech's Products	257
8.74	Pervasis Therapeutics, Inc.	258
8.74.1	Pervasis' Clinical Focus	258
8.74.2	Power of Endothellium	258
8.74.3	Therapeutic Applications of Pervasis' Products	259
8.74.3.1	Arteriovenous (AV) Access for Hemodialysis	259
8.74.3.2	Peripheral Arterial Disease	259
8.75	Pleuron	260
8.75.1	Pleuron's Technology	260
8.76	Pluristem Therapeutics, Inc.	260
8.76.1	Pluristem's PluriX™ 3D Bioreactor	260
8.76.2	Pluristem's PLacental eXpanded (PLX) Cells	260
8.76.3	PLX-PAD for Peripheral Artery Disease	260
8.76.4	PLX-IBD for Inflammatory Bowel Disease	261
8.76.5	PLX-MS for Multiple Sclerosis	261
8.76.6	PLX-STROKE for Ischemic Stroke	261
8.77	RegeneRx	261
8.78	ReNeuron Group plc	261
8.78.1	ReNeuron's Platform Technologies	262
8.78.2	ReNeuron's Cell Therapy Programs	263
8.78.3	ReNeuron's ReN001 for Stroke	263
8.78.4	ReNeuron's ReNcell® Products	264
8.79	Revivicor, Inc.	264
8.79.1	Revivicor's Xenografting Technology	264
8.79.2	Revivicor's Islet Transplantation Technology	264
8.79.3	Revivicor's Infectious Disease Platform Technologies	265
8.80	Saneron CCEL Therapeutics, Inc.	265
8.80.1	Saneron's U-Cord-Cell™ Program	265
8.80.2	Saneron's Sert-Cell™ Program	265
8.81	Sangamo BioSciences, Inc.	265
8.81.1	Sangamo's ZFP Therapeutic Product Development Programs	266
8.81.2	ZFP Therapeutic Pre-clinical Stage Programs	266
8.81.2.1	Neuropathic Pain (Cancer Pain)	266
8.81.2.2	Nerve Regeneration—Spinal Cord Injury (SCI) and Traumatic Brain Injury (TBI)	266
8.81.2.3	Parkinson's Disease (PD)	267
8.81.2.4	Stroke	267
8.81.2.5	ZFP Therapeutic Research Programs	267
8.81.3	Funding from Research Foundations	267
8.81.3.1	The Juvenile Diabetes Research Foundation International	267
8.81.3.2	The Michael J. Fox Foundation	267
8.81.3.3	The Bill and Melinda Gates Foundation	267
8.81.4	Sangamo's Research and Development Expenses	267

8.81.5	Sangamo's Business Performance	268
8.82	StemCells, Inc.	268
8.82.1	StemCell's Cellular Medicine Programs	269
8.82.2	StemCells' Enabling Technologies Program	270
8.82.3	StemCells' Patents, Proprietary Rights and Licenses	270
8.83	Stem Cell Authority Ltd.	271
8.83.1	The "Miracle" Mesenchymal Stem Cell—Mirachymal Stem Cells	272
8.84	Stem Cell Innovations (SCI)	272
8.84.1	SCI's Research and Development	272
8.84.2	SCI's Services	272
8.84.3	PluriCells™ and Derivatives	272
8.84.4	ACTIVTox®	273
8.84.5	PredictivTox®	273
8.84.6	Endogenous Protein Production	273
8.85	Stem Cell Sciences KK	273
8.85.1	SCS KK's Product/Service	273
8.85.1.1	CultiCell Medium for Embryonic Stem Cells	273
8.85.1.2	Contract/Sponsored Research on ES-derived Functional Cells	274
8.86	SyntheMed, Inc.	274
8.86.1	Repel-CV® Adhesion Barrier	274
8.86.2	Resolve™ Adhesion Barrier Instillate	274
8.86.3	Repel™ Adhesion Barrier	275
8.86.4	SpineShield™ Adhesion Barrier Film	275
8.86.5	Relieve™ Adhesion Barrier Gel	275
8.86.6	SinusShield™ Adhesion Prevention Film	275
8.87	t2cure GmbH	275
8.87.1	BMCs in Regenerative Therapies	275
8.87.2	t2cure's Product Development Pipeline	275
8.88	Tengion	276
8.88.1	Tengion's Pipeline Overview	276
8.89	TiGenix	277
8.89.1	ChondroCelect®	277
8.89.2	Chondromimetic	277
8.89.3	TGX002	277
8.89.4	TGX003	277
8.90	Thermogenesis Corp.	278
8.90.1	Products from Thermogenesis	278
8.90.1.1	AutoXpress™ Platform or AXP®	278
8.90.1.2	MarrowXpress	278
8.90.1.3	BioArchive® System	278
8.90.1.4	Res-Q™	278
8.90.1.5	Thermoline™	278
8.90.1.6	CryoSeal® Fibrin Sealant (CryoSeal) System	278
8.90.2	Thermogenesis' Business Performance	279

INDEX OF FIGURES

Figure 2.1: Geographic Distribution of 73 TERM Firms in the Five Focus Countries, 2009	29
Figure 2.2: Geographic Distribution of the 15 TERM Firms in Germany, 2009	30
Figure 2.3: Geographic Distribution of the Five TERM Companies in the U.K., 2009	30
Figure 2.4: The Potential Uses of Embryonic Stem Cells	32
Figure 2.5: Cell Culture Products by Market Segment	34
Figure 2.6: Estimated Global Market for Cell and Tissue Analysis Products, 2008-2014	35
Figure 2.7: Growth in Size of Cell Therapy Industry, 2000-2008	40
Figure 2.8: Percent Break-up of Cell Therapy Companies by Product Type, 2008	41

Figure 2.9: Location of Primary Tissue Engineering Companies by Geography, 2008-2009	42
Figure 2.10: Breakdown of Primary Cell Therapy Products on Market by Geography, 2008-2009	44
Figure 2.11: The Geographical Distribution of Clinical Trials, 2008-2009	47
Figure 2.12: Implantation of a Hydrogel at the Site of an Injured Tissue	57
Figure 2.13: Implantation of CS-PEG Hydrogel	57
Figure 2.14: Implantation of CMP-PEG Scaffold	58
Figure 4.1: Global Market for Regenerative Medicine Products, 2008-2013	79
Figure 4.2: Estimated market for Regenerative Cell Therapy Products for Orthopedics, 2008-2012	80
Figure 4.3: Estimated U.S. Market for Regenerative Medicine Products, 2009-2014	80
Figure 4.4: Estimated U.S. Market for Bone Grafting/Bone Replacement, 2009-2014	81
Figure 4.5: Estimated U.S. Market for Bone Growth Stimulating Substances, 2009-2014	81
Figure 4.6: Estimated U.S. Market for Regenerative Products for Cartilage Repair, 2009-2014	82
Figure 4.7: Estimated Market for Stem cells, 2008-2012	84
Figure 4.8: Estimated Market for Cell Therapy Products in the U.S., 2009-2018	85
Figure 4.9: Estimated Global Market for Cord Blood Stem Cells, 2010-2015	86
Figure 4.10: Worldwide Growth of Public Cord Blood Banks, 2005-2009	86
Figure 4.11: Worldwide Growth of Private Cord Blood Banks, 2005-2009	87
Figure 5.1: Cell-based Business Models	89
Figure 5.2: Current Autologous Business Models	91
Figure 5.3: Current Allogeneic Business Models	92
Figure 7.1: CIRM's Grant Awards by Category, 2009	109
Figure 7.2: CIRM's Funding by Disease Application, 2009	110
Figure 7.3: CIRM's Funding by Disease Category	111
Figure 7.4: Estimated Increase in Worldwide Funding for RM Research, 2008-2018	117
Figure 8.1: Aastrom's Investment in Research and Development, 2007-2009	121
Figure 8.2: Aastrom's Business Performance, 2005-2009	122
Figure 8.3: ACT's Business Performance, 2008 and 2009	125
Figure 8.4: ACT's Investment in Research and Development, 2008 and 2009	125
Figure 8.5: Aranesp® (Darbepoetin Alfa)'s Sales in the U.S. and International Market, 2007-2009	136
Figure 8.6: U.S. Market for Epogen®, 2007-2009	136
Figure 8.7: Global Market for Neulasta®, 2007-2009	137
Figure 8.8: Global Market for Enbrel® (Etanercept), 2007-2009	137
Figure 8.9: Global Market for Sensipar® (Cinacalcet), 2007-2009	138
Figure 8.10: Global Market for Vectibix® (Panitumumab), 2007-2009	139
Figure 8.11: Global Market for Nplate® (Romiplostim), 2007-2009	139
Figure 8.12: Amgen's Three Large Wholesale Customers, 2007-2009	140
Figure 8.13: Amgen's Overall U.S. and International Market, 2007-2008	140
Figure 8.14: Athersys' Investment and Development, 2007-2009	154
Figure 8.15: Athersys' Business Performance, 2005-2009	154
Figure 8.16: Current Capitalization of Cardio3's Investors, 2009	170
Figure 8.17: Celgene's Business Performance, 2005-2009	181
Figure 8.18: Curis' Business Performance, 2005-2009	198
Figure 8.19: Genzyme's Business Performance, 2005-2009	213
Figure 8.20: Genzyme's Percent of Revenue by Business Group, 2009	213
Figure 8.21: Geron's Business Performance, 2005-2009	220
Figure 8.22: Geron's Investment in Research and Development, 2005-2009	221
Figure 8.23: Integra's Investment in Research and Development, 2007-2009	229
Figure 8.24: Integra's Business Performance, 2005-2009	230
Figure 8.25: NeuroNova's Share Holders as of June, 2009	247
Figure 8.26: Orthovita's Business Performance, 2005-2009	255
Figure 8.27: Sangamo's Investment in Research and Development, 2007-2009	268
Figure 8.28: Sangamo's Business Performance, 2005-2009	268

INDEX OF TABLES

Table 2.1: Number of TERM Companies Identified in the Five Focus Countries, 2009	25
Table 2.2: Number of TERM Companies Developing Stem Cells Seeded to Scaffolds, 2009	25
Table 2.3: Number of Firms with Focus on Skin, Cartilage, Bone and Urological Applications, 2009	26
Table 2.4: Number of Firms Focusing on Cardiovascular Applications, 2009	27
Table 2.5: Number of Firms with a Focus on Neurological Applications, 2009	27
Table 2.6: Number of Firms Focused on Pancreas, Liver and Kidney Applications, 2009	28
Table 2.7: Number of Companies Focused on Autologous and Allogeneic Products, 2009	28
Table 2.8: Geographic Distribution of 37 U.S. TIRM Firms, 2009	29
Table 2.9: Geographic Location of 11 out of 13 TERM Firms in Japan, 2009	30
Table 2.10: Geographic Distribution of the Three TERM Firms in Sweden, 2009	31
Table 2.11: Number of Patients Treated with Cell Therapeutics, 1988-2010	33
Table 2.12: Some Selected Suppliers of In vitro Test Kits and Their Products	35
Table 2.13: Suppliers of Cells and Tissues	36
Table 2.14: Selected Suppliers of Media and Reagents	37
Table 2.15: Selected Providers of Equipments in Stem Cell Research	37
Table 2.16: Selected Providers of Computer Software for Stem Cell Research	39
Table 2.17: Geographical Distribution of Stem Cell-related Tissue Engineering Companies, 2008	41
Table 2.18: Breakdown of Cell Therapy Firms by Country, 2008-2009	43
Table 2.19: Cell Therapy Products on the Market by Type and Application Area, 2008-2009	44
Table 2.20: Data on Sales and Application for Skin and Cartilage Products, 2006-2008	45
Table 2.21: Reagent Sales by Selected Stem Cell Companies, 2008	46
Table 2.22: Sales of Secondary Products, 2007	46
Table 2.23: Disease Focus of Clinical Trials, 2008-2009	48
Table 2.24: Stem Cell Products in Phase II/III Trials, 2008-2009	49
Table 2.25: Licensing Activities in Pharmaceutical and Cell Therapy Industries	54
Table 2.26: Investment Activity in Cell Therapy Sector	54
Table 2.27: Novel Partnership by Large Pharmaceuticals with Universities	54
Table 2.28: Cell Therapy Companies with Greater than Ten Million by Market Cap, 2008	55
Table 3.1: Regenerative Medicine Product Development Status, 2008	62
Table 3.2: Top Ten Regenerative Medicine Products, 2008	66
Table 3.3: Wound Healing Products	72
Table 4.1: Worldwide Estimates of Key Industry Parameters, 2007	83
Table 4.2: Potential U.S. Populations for Cell-based Therapies	84
Table 5.1: The Required Elements of a Manufacturing Facility	94
Table 5.2: Cell Therapy CMO Qualification Audit: Points to Investigate	95
Table 6.1: Diseases with Potential Applications for Regenerative Medicine	97
Table 7.1: Stem Cell Policies in North America	104
Table 7.2: Stem Cell Policies in South America	105
Table 7.3: Stem Cell Policies in Europe	106
Table 7.4: Stem Cell Policies in Asia/Oceania	107
Table 7.5: CIRM Funded Grants To-Date	108
Table 7.6: List of Upcoming Request for Applications (RFAs) Showing Commitments from Funding Partners	110
Table 7.7: Recipients of Funds from Connecticut Stem Cell Research Program, 2009	112
Table 7.8: Maryland Stem Cell Research Fund, 2008	114
Table 7.9: NJCST's Award of Grants for Stem Cell Research, 2008	114
Table 7.10: NYSTEM's IIRP Awards, 2008	115
Table 7.11: NIH Funding for Regenerative Medicine and Stem Cell Research, 2003-2009	119
Table 7.12: NIH Funding for Various Types of Stem Cell Research, 2004-2009	119
Table 8.1: Patents Owned by ACT	124
Table 8.2: Patents Owned by ACT's Subsidiary Mytogen, Inc.	124
Table 8.3: Patents Licensed to ACT by the University of Massachusetts	124
Table 8.4: Alseres' Product Pipeline, 2009	129
Table 8.5: Amgen's Pipeline of Products	134
Table 8.6: Amgen's Approved Products	135

Table 8.7: AnGes' Current Pipeline Status, 2010	144
Table 8.8: Angioblast's Product Development Overview	146
Table 8.9: Angion's Product Pipeline	146
Table 8.10: Angion's Product Pipeline	148
Table 8.11: Arteriocyte's Product Pipeline	150
Table 8.12: Developmental Status of Athersys' Key Programs, 2010	151
Table 8.13: Biohearts Pipeline Product Candidates	157
Table 8.14: BioLines Product Pipeline, 2010	159
Table 8.15: BioMimetic's Current Product Candidates and Target Indications	160
Table 8.16: BioMimetic's Clinical Studies	161
Table 8.17: BioMimetic's Investment in Research and Development, 2005-2009	161
Table 8.18: BrainStorm's Intellectual Property	168
Table 8.19: Cardio3's Promising Product Pipeline	168
Table 8.20: Cellerix's Product Pipeline	180
Table 8.21: Celgene's Leading Product Candidates	183
Table 8.22: Private Cord Blood Banking vs. Public Donation	196
Table 8.23: Curis' Current Research and Development Programs and their Status	197
Table 8.24: Curis' Revenues from Research and Development, 2008 and 2009	198
Table 8.25: Regulatory Status of Celution® System	199
Table 8.26: Regulatory Status of PureGraft™ and CelBrush™	200
Table 8.27: Develogen's Pipeline Overview	202
Table 8.28: Epistem's Emerging Pipeline of Protein Therapeutics	207
Table 8.29: FivePrime's Product Pipeline	209
Table 8.30: FivePrime's Collaborations	209
Table 8.31: Gamidia's Pipeline Products	211
Table 8.32: Genzyme's Pipeline of Products	217
Table 8.33: Cancer Therapeutics and Diagnostic Products being Developed by Geron	219
Table 8.34: The hESC-derived Product Candidates Developed by Geron and its Collaborators	219
Table 8.35: Geron's Patent Portfolio	220
Table 8.36: Hydra's Product Pipeline	225
Table 8.37: Intercytex' Product Pipeline	225
Table 8.38: Kiadis' Product Pipeline	239
Table 8.39: NeuralStem's Issued and Pending Patents	245
Table 8.40: NeuroNova's Product Pipeline	246
Table 8.41: Orthovita's Existing Orthobiologic and Biosurgery Products	252
Table 8.42: Orthovita's Biosurgery Products	254
Table 8.43: Osiris' Therapeutic Product Pipeline	257
Table 8.44: Pervasis' Product Pipeline	259
Table 8.45: RegeneRx's Product Development Pipeline	261
Table 8.46: Summary of Sangamo's Current Clinical Programs	266
Table 8.47: Current Status of StemCells' Therapeutic Product Development Programs	269
Table 8.48: StemCells' Cell Culture Products	270
Table 8.49: StemCells' Patents Covering Stem and Progenitor Cells and Research Tools	271
Table 8.50: t2cure's Product Development Pipeline	276
Table 8.51: Tengion's Product Candidates Pipeline	277
Table 8.52: Thermogenesis' Business Performance by Geographic Area, 2007-2009	279

1. Overview

1.1 Statement of Report

Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms—like the starfish—man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine.

As such, the purpose of this report is to describe the emerging field of regenerative medicine. The areas covered in this study include: available and emerging technologies in the field, the U.S. and global market size for regenerative medicine products, and the profiles of companies that are focusing on regenerative medicine sector. The main objectives of this analysis are:

- Estimate the current and future U.S. and global markets for regenerative medicine.
- Examine market drivers that have resulted in the global race for regenerative medicines.
- Assess market opportunities and the potential market pertaining to the disease indications.
- Discuss product development challenges in relation to regulatory constraints, legislative constraints and technical challenges.
- Analyze the need for regenerative medicine for the different disease indications.
- Understand the impact of current products and the future of regenerative medicine industry.
- Provide insight into the regenerative medicine products in the pipeline and the companies that strive to bring these products to the market in the immediate future.
- Evaluation global activity in regenerative medicine with specific contributions from the top-ranking five countries: U.S., Japan, Germany, U.K. and Sweden.
- Analyze the segments in regenerative medicine such as scaffolds, cells and tissues and biomolecules.
- Gain insight into the current applications of regenerative medicine in bone, heart, neurons, pancreas, eye and tooth.
- Explore drug discovery efforts in relation to regenerative medicine.
- Analyze the usual hurdles regenerative medicines are encountering to reach the market and the right path to the market for these products.
- Review the current licensing, investing and partnering activities in regenerative medicine sector.
- Assess business models and requirements for a successful regenerative medicine industry.
- Examine funding scenario for the regenerative medicine sector.
- Identify the key players in the regenerative medicine industry and their contribution to this emerging therapy.

Key questions answered in this study are:

- What according to the U.S. National Institute of Health (NIH) are the products that come under the phrase “regenerative medicine”?
- What disease conditions offer the greatest potential for regenerative medicines?
- What is the current global market for regenerative medicine?
- How much of clinical development activities are taking place globally in regenerative medicine sector?
- How many companies are involved in the development of regenerative medicine products?
- How many patents have been issued for regenerative medicine products?
- How long would it take to develop tissues on demand?
- What market drivers are responsible for the global race in regenerative medicine?
- Which healthcare segments can make an easy entry into the regenerative medicine market?

- What regulatory and technical challenges are being confronted by the regenerative medicine industry?
- Which countries are in the forefront of developing regenerative medicine?
- What are the current promising developments in regenerative medicine sector?
- Which countries have made strong commitments to achieve supremacy in the race for these future-medicines?
- What is the latest position of the clinical studies and product pipe line in regenerative medicine sector?
- How long it will take for the regenerative medicine therapies to become the standard of care to replace all damaged tissues and organ systems in the body?
- How much of venture capital fund was invested into the regenerative medicine sector?
- What is the financial commitment made by governments other than the U.S., such as Japan, China, South Korea and Singapore?
- What is the potential population in the U.S. for cell therapies?
- Do the developing countries which comprise the largest populations offer scope for the regenerative medicine product?
- What are the probable top-ten applications of regenerative medicines in the developing countries?
- What are the top-ten regenerative medicine products available in the market place?
- What are the available wound healing regenerative medicine products in the market?
- What are the cartilage regeneration products available in the market?
- How many companies are involved in the development of skin, cartilage, bone, urological products?
- How many companies are focused on the development of regenerative cardiovascular products?
- How many companies are engaged in the development of regenerative neurological products?
- How many firms concentrate on pancreas, liver and kidney products?
- Which firms are involved in the development of ophthalmic products?
- Which companies are focused on the development of dental regenerative products?
- Which companies are focusing on the manufacture of growth factors?
- Which companies are involved in marketing drug screening products for toxicology tests?
- Which companies are associated with developing biomaterials in relation to regenerative medicine?
- Is there an easy market path to products of regenerative medicine?
- How many companies develop autologous and allogeneic cell therapy products?
- What are the different business models suitable for the different types of regenerative medicine products?
- What are the requirements for the commercial manufacturing of regenerative medicine products?
- What are the different funding sources in the U.S. for the development of regenerative medicine products?

This report contains:

- Current market opportunities for regenerative medicine products.
- Product development challenges confronted by the regenerative medicine industry.
- A brief discussion on the need for regenerative medicine and the advantages of cell therapy over the conventional pharmaceutical medicines.
- A brief note on the current state of regenerative medicine.
- The future direction of the emerging regenerative therapy treatments.
- The overall picture of pipeline products in regenerative medicine sector and the companies involved.
- A brief note on the projected time-line for regenerative medicine.
- A market projection for global regenerative medicine products.
- A short note on the potential number of U.S. patients requiring regenerative therapy as based on an estimate from the American Heart Association, the American Autoimmune Disease Association, American Burn Association, etc.
- A detailed discussion on the potential market for regeneration therapies in the thickly populated but economically weak developing countries.
- Listing and explaining the most popular regenerative medicine products in the market.
- Presentation of the global picture of the regenerative medicine industry with particular reference to the leading countries, such as U.S., Japan, Germany, U.K. and Sweden.

- Number of firms engaged in regenerative medicine (RM) products for skin, cartilage, bone and neurological applications in the above five leading countries.
- Number of RM firms focusing on cardiovascular applications in the five leading countries.
- Number of RM firms concentrating on neurological applications in the five leading countries.
- Number of RM firms specializing on pancreas, liver and kidney applications.
- Leading RM firms in ophthalmic applications.
- Key RM players in dental applications.
- Leading companies in the field of drug discovery using cells and tissues as tools.
- Leading firms focusing on biomaterials used in regenerative therapy.
- A detailed discussion on RM product's path to market.
- A detailed account on business models and requirements for a successful RM industry.
- A brief note on in-house and contract manufacturing options for an RM industry.
- A note on global funding for RM industry.
- A brief introduction to U.S. federal funding for RM in the past, present and future.
- Listing of all the diseases with potential applications for regenerative medicines.
- A brief discussion on international collaboration on RM research.
- In-depth profiles of 90 companies involved in research and development (R&D) of products in biomaterials, cell therapy products and tools related to RM.

1.2 Scope of this Report

This report provides a thorough overview of regenerative medicine (RM) sector together with analyses of the funding trends, intellectual property, market opportunities and emerging areas of applications, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures in this emerging field. The report enables the reader gain in-depth knowledge about the various ongoing research programs carried out in the U.S. universities and other research centers. Since regenerative medicine is an emerging field, only about five countries such as the U.S., Japan, Germany, U.K. and Sweden seem to play an important role, and this report gives the details such as the number of firms and the types of products manufactured in these five focus countries. The various business models in cell therapy have been described in detail so that the companies expanding their operations can have an insight into the best model suitable for their new ventures. The appendix part of this analysis carries an exhaustive list of consultants who are in this field for several years offering consultancy services for new entrants into this field. This study also covers the companies that are actively developing and marketing RM products. Other TriMark Publications reports related to different healthcare segments can be found at <http://www.trimarkpublications.com>.

1.3 Methodology

The author of this report is a retired college professor with three decades of experience in teaching biochemistry, biotechnology, pharmacology, environmental biology and horticulture. The detailed study of this report is based mainly on the publications of primary research on regenerative medicine, as well as information from venture capital firms. For the publicly held companies, the annual reports, 10-K filings and financial reports were examined. Information available from the proprietary databases at Biotechnology Associates and from the private data stores of TriMark Publications was also used in preparing this report. Important data sources include American Heart Association, American Autoimmune Related Disease Association, American Burn Association, *World Stem Cell Report 2008 and 2009*, Swedish Governmental Agency for Innovative System (VINNOVA) and research centers from the U.S. universities. The market data given in this report are based on available market data from press releases and company annual reports. Company profiles were gathered from the annual reports, conference proceedings and Internet searches. The information set forth in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information, any omission or the results obtained by the use of such information.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects and Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark's research in the past three years as part of this data collection. We also extract qualified data feeds from e-questionnaire responses and primary research responses for this compilation.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government affiliated trade releases, and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations. The report conclusions are verified through intensive interviewing of the top-ranking companies in the industry.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners.

1.4 Executive Summary

This study discusses the current state and activities of an up-coming and fast-developing knowledge field of regenerative medicine (RM). RM has been made possible by tissue engineering and, therefore, much of the discussion in this study is about both tissue engineering and regenerative medicine (TERM). TERM focuses on medical treatments to repair tissues and organs using bioengineered materials, cellular technologies and some forms of implants. The report also aims to identify the future initiatives that would stimulate knowledge creation and innovation processes leading to new therapies and products beneficial to patients in a global perspective.

The science of tissue engineering includes the development of therapeutic solutions based on a combination of scaffolds based on biomaterials, cells and tissue and biomolecules. Although, the report mentions several countries in this sector, only five of these countries (U.S., Japan, Germany, U.K., and Sweden) are the focus-countries of this analysis. In these focus-countries, there are about 303 companies actively engaged in regenerative medicine and 77 of these companies are engaged in the development of organ-specific and tissue-engineered products. About 230 companies are pharmaceutical industries focusing on drug discovery and development by using stem cells. Some of them are developing drugs to be used in regenerative medicine. Some are engaged in the development of tools

required for used in TERM applications. There are also some companies focusing on biomaterials for RM applications.

Almost all categories of RM companies are found in the U.S., but the country's strength is more pronounced in neurology, pancreas, kidney and liver applications. Germany is strong in skin, cartilage, bone and urological applications. Only the U.S. and Germany have projects in cardiovascular applications in clinical trials. Japanese companies are sound in skin, cartilage, bone, cardiovascular and urological applications. Companies in U.K. are active in skin, cartilage, bone and urological applications. As the companies currently engaged in biocompatible materials may face severe competition, they too are likely to enter the RM field. Although a huge market has been predicted for RM products in future, for many companies, this is still wishful thinking than a reality. The specific challenges for RM firms to reach the market include: public and political acceptance, selection of type of cell source, types of business model, and benefits/drawbacks of a firm's specific geographic location.

Today, Europe has a common regulation aiming at advanced-therapy medicinal products that include products based on genes, cells and tissues and centralized marketing authorization procedure. Europe, thus, faces a much improved regulatory situation. There are, however, variations as to policies, volume of investments, profile areas and applied research in the five focused countries. The U.S. leads in scientific output in terms of publication volume. Asian countries such as China, South Korea and Taiwan also are displaying an interest in this emerging field.

Among the individual research organizations, Harvard University is outstanding in the field of stem cell research. Other than the U.S. organizations, the top universities in stem cell research are located in countries like Japan, Sweden, England, Switzerland, Germany, Singapore, Italy and Canada. In stem cell research relating to neuroscience, the top non-U.S. organization is the Japanese Kyoto University in third position and the Swedish Karolinska Institutet is the top European organization.

In biomaterials research fields, the U.S., Japanese, German and Singaporean research environments hold the most prominent positions. The Universities of Toronto, Kyoto, Singapore, Bern, Seoul, Michigan, Bologna and Texas hold top positions in the statistics depending on biomaterial field. Swedish researchers are strong in the field of osteointegration, and in this field, Gothenburg University seems to outperform most other organizations.

This study provides separate comprehensive analytics for the U.S., Japan, Germany, U.K. and Sweden. Annual data are provided for tissue engineering and regenerative medicine products for the years 2008 to 2013. The report profiles 90 companies including many important players globally such as Amgen, Inc., Arthersys, Inc., Bioheart, Inc., Biomet, BioMimetic Therapeutics, Inc., Cellartis AB, Cellerix, Celgene Corporation, Cytori Therapeutics, Inc., Gamida Cell Ltd., Genzyme Corporation, Geron Corporation, Organogenesis, Inc., Osiris Therapeutics, Inc., Reneuron Group plc, Stryker Corporation, etc. The aim of this study is to provide, an overview of the global commercial landscape in regenerative medicine, the strength of the participating companies, and the scope for the hopeful new entrants into the sector. The time is ripe for the pharmaceutical giants to enter the new field and contribute their might to the development of cell therapies for the betterment of human health.